WallStreetZenWallStreetZen

NASDAQ: BLFS
Biolife Solutions Inc Stock Forecast, Predictions & Price Target

Analyst price target for BLFS

Based on 1 analyst offering 12 month price targets for Biolife Solutions Inc.
Min Forecast
$22.00+30.49%
Avg Forecast
$22.00+30.49%
Max Forecast
$22.00+30.49%

Should I buy or sell BLFS stock?

Based on 1 analyst offering ratings for Biolife Solutions Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BLFS stock forecasts and price targets.

BLFS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-04

1 of 1

Forecast return on equity

Is BLFS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is BLFS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BLFS revenue forecast

What is BLFS's revenue in the next 2 years based on estimates from 3 analysts?
Avg 1 year Forecast
$117.1M-18.29%
Avg 2 year Forecast
$141.7M-1.1%
BLFS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BLFS revenue growth forecast

How is BLFS forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
5.1%
Industry
8.57%
Market
9.92%
BLFS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BLFS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BLFS vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
BLFS$16.86$22.00+30.49%Strong Buy
ATRI$398.97N/AN/A
ZJYL$3.92N/AN/A
EMBC$10.40$16.00+53.85%Strong Sell
ATRC$22.61$48.00+112.30%Strong Buy

Biolife Solutions Stock Forecast FAQ

Is Biolife Solutions Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BLFS) stock is to Strong Buy BLFS stock.

Out of 1 analyst, 1 (100%) are recommending BLFS as a Strong Buy, 0 (0%) are recommending BLFS as a Buy, 0 (0%) are recommending BLFS as a Hold, 0 (0%) are recommending BLFS as a Sell, and 0 (0%) are recommending BLFS as a Strong Sell.

If you're new to stock investing, here's how to buy Biolife Solutions stock.

What is BLFS's revenue growth forecast for 2024-2025?

(NASDAQ: BLFS) Biolife Solutions's forecast annual revenue growth rate of 5.1% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Biolife Solutions's revenue in 2024 is $143,271,000.On average, 3 Wall Street analysts forecast BLFS's revenue for 2024 to be $5,303,089,800, with the lowest BLFS revenue forecast at $4,416,750,000, and the highest BLFS revenue forecast at $6,650,040,000.

In 2025, BLFS is forecast to generate $6,419,010,000 in revenue, with the lowest revenue forecast at $5,073,600,000 and the highest revenue forecast at $7,841,430,000.

What is BLFS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BLFS) forecast ROA is N/A, which is lower than the forecast US Medical Instruments & Supplies industry average of N/A.

What is BLFS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BLFS price target, the average BLFS price target is $22.00, with the highest BLFS stock price forecast at $22.00 and the lowest BLFS stock price forecast at $22.00.

The Wall Street analyst predicted that Biolife Solutions's share price could reach $22.00 by Apr 4, 2025. The average Biolife Solutions stock price prediction forecasts a potential upside of 30.49% from the current BLFS share price of $16.86.

What is BLFS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BLFS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.